Terminated PHASE2 INTERVENTIONAL 2-arm NCT03275376

Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma

Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma: A Randomized Controlled Study

Sponsor: Taichung Veterans General Hospital

Conditions Overall Survival Tumor Responses

Interventions Atorvastatin 10mg Placebo Oral Tablet

Updated 9 times since 2017 Last updated: Mar 14, 2021 Started: Dec 21, 2017 Primary completion: Dec 21, 2020 Completion: Mar 13, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow in patient enrollment

This PHASE2 trial investigates Overall Survival and Tumor Responses and is currently terminated or withdrawn. Taichung Veterans General Hospital leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2021 — Jul 2024 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

Nov 2018 — Apr 2020 [monthly]

Recruiting PHASE2
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taichung Veterans General Hospital

Data source: Taichung Veterans General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taichung, Taiwan